Skip to main content
Top
Published in: Journal of Gastroenterology 6/2003

01-06-2003 | Letter to the editor

Primary coexistent neuroendocrine carcinoma, hepatoid adenocarcinoma, and tubular adenocarcinoma of the stomach with focal trophoblastic differentiation in metastatic lymph nodes

Authors: Tatsuya Okamoto, Keizo Ogasahara, Masato Fujiki, Hidekazu Takagi, Hiroyoshi Ikeda, Tomokazu Makino, Takeo Moriga, Kazuyuki Kawamoto, Kaoru Sano, Yasuo Yoshida, Tadashi Itoh, Hidenari Takasan, Yoji Wani, Yukihiro Kono

Published in: Journal of Gastroenterology | Issue 6/2003

Login to get access
Metadata
Title
Primary coexistent neuroendocrine carcinoma, hepatoid adenocarcinoma, and tubular adenocarcinoma of the stomach with focal trophoblastic differentiation in metastatic lymph nodes
Authors
Tatsuya Okamoto
Keizo Ogasahara
Masato Fujiki
Hidekazu Takagi
Hiroyoshi Ikeda
Tomokazu Makino
Takeo Moriga
Kazuyuki Kawamoto
Kaoru Sano
Yasuo Yoshida
Tadashi Itoh
Hidenari Takasan
Yoji Wani
Yukihiro Kono
Publication date
01-06-2003
Publisher
Springer-Verlag
Published in
Journal of Gastroenterology / Issue 6/2003
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-003-1128-5

Other articles of this Issue 6/2003

Journal of Gastroenterology 6/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine